We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-9.52%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$985M
AUM Growth
-$142M
Cap. Flow
+$49.9M
Cap. Flow %
5.07%
Top 10 Hldgs %
58.04%
Holding
76
New
11
Increased
24
Reduced
21
Closed
19

Top Buys

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$54.6M
2
PCVX icon
Vaxcyte
PCVX
+$34.3M
3
GKOS icon
Glaukos
GKOS
+$21.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$21.2M
5
CYH icon
Community Health Systems
CYH
+$17.5M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$38M
2
INSP icon
Inspire Medical Systems
INSP
+$19.5M
3
VTRS icon
Viatris
VTRS
+$15.8M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$14.9M
5
EW icon
Edwards Lifesciences
EW
+$12.6M

Sector Composition

Rank Sector Weight
1 Healthcare 88.54%
2 Miscellaneous 11.4%
3 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GMED icon
26
Globus Medical
GMED
$11.1B
$14.1M 1.43%
+192,893
New +$15.9M
CLDX icon
27
Celldex Therapeutics
CLDX
$3.07B
$12.6M 1.28%
696,499
-23,337
-3% -$521K
QQQ icon
28
Invesco QQQ Trust
QQQ
$489B
$11.3M 1.14%
+24,003
New +$12.2M
ALGN icon
29
Align Technology
ALGN
$11.2B
$7.83M 0.8%
+49,277
New +$9.67M
TFX icon
30
Teleflex
TFX
$5.92B
$7.83M 0.79%
56,630
-5,106
-8% -$827K
MOH icon
31
Molina Healthcare
MOH
$10.4B
$7.82M 0.79%
+23,735
New +$7.17M
HUM icon
32
Humana
HUM
$46.3B
$7.4M 0.75%
27,970
+5,288
+23% +$1.43M
ELV icon
33
Elevance Health
ELV
$85.5B
$6.83M 0.69%
15,698
-13,480
-46% -$5.41M
NAMS icon
34
NewAmsterdam Pharma
NAMS
$3.1B
$5.75M 0.58%
280,951
+5,589
+2% +$124K
GOSS icon
35
Gossamer Bio
GOSS
$83.2M
$4.29M 0.44%
3,896,841
-1,081,617
-22% -$1.25M
ZBIO
36
Zenas BioPharma
ZBIO
$2.04B
$3.52M 0.36%
445,588
+273,485
+159% +$2.14M
MNKD icon
37
MannKind Corp
MNKD
$1.27B
$3.51M 0.36%
697,710
-213,315
-23% -$1.19M
MRUS
38
DELISTED
Merus
MRUS
$2.96M 0.3%
70,329
+2,071
+3% +$90.3K
RGEN icon
39
Repligen
RGEN
$9.95B
$2.35M 0.24%
18,452
-35,614
-66% -$5.48M
NVAX icon
40
Novavax
NVAX
$1.53B
$2.34M 0.24%
+365,523
New +$3.02M
LQDA icon
41
Liquidia Corp
LQDA
$6.06B
$2.22M 0.23%
150,480
-420,825
-74% -$6.14M
FTRE icon
42
Fortrea Holdings
FTRE
$1.79B
$2.21M 0.22%
293,275
-108,458
-27% -$1.53M
ETNB
43
DELISTED
89bio
ETNB
$2.21M 0.22%
+303,731
New +$2.66M
MRVI icon
44
Maravai LifeSciences
MRVI
$1.14B
$2.08M 0.21%
+942,454
New +$3.72M
AVTR icon
45
Avantor
AVTR
$9.86B
$1.99M 0.2%
122,823
-45,546
-27% -$863K
ICLR icon
46
Icon
ICLR
$13.1B
$1.9M 0.19%
10,840
-8,412
-44% -$1.63M
IFRX icon
47
InflaRx
IFRX
$329M
$1.71M 0.17%
1,675,978
+1,183,526
+240% +$2.23M
AMRN
48
Amarin Corp
AMRN
$295M
$1.52M 0.15%
169,960
+94,130
+124% +$996K
STRO icon
49
Sutro Biopharma
STRO
$339M
$1.49M 0.15%
229,226
+159,785
+230% +$2.52M
ITOS
50
DELISTED
iTeos Therapeutics
ITOS
$1.31M 0.13%
220,196
– –
1
2
3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q1 2025 Portfolio in Review

As of Q1 2025, Eversept Partners held 76 positions worth $985M, down 13% from $1.13B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Eversept Partners deployed $49.9M of net new capital in Q1 2025, opening 11 new positions and adding to 24 existing holdings. Its largest new stake was Glaukos: 158,957 shares worth $15.6M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was GSK, an estimated $38M trimmed.

  • Eversept Partners's largest Q1 2025 buy was Glaukos: 158,957 shares worth $15.6M.
  • Eversept Partners added most to Syndax Pharmaceuticals in Q1 2025, an estimated $54.6M increase.
  • Eversept Partners's biggest Q1 2025 reduction was GSK, cutting an estimated $38M.
  • Eversept Partners fully exited Viatris in Q1 2025, selling an estimated $15.8M.
  • Eversept Partners's ten largest holdings make up 58% of its $985M portfolio in Q1 2025.
  • Eversept Partners opened 11 new positions and closed 19 in Q1 2025.
  • Eversept Partners's portfolio value fell 13% quarter-over-quarter to $985M.

Based on Eversept Partners's 13F filing for Q1 2025, filed 15 May 2025.